Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First

Similar CAR-T Will Carry The Same Cost As Yescarta

3D illustration of T cells attacking a cancer cell (CAR-T cell therapy) - Illustration

More from New Products

More from Scrip